期刊文献+

《2015年美国国立综合癌症网络胰腺癌临床实践指南(V2版)》外科相关部分解读 被引量:14

The discussion on the surgical issues related to NCCN clinical practice guidelines in oncology for pancreatic adenocarcinoma(V2.2015 )
下载PDF
导出
摘要 胰腺癌是消化系统中恶性程度最高的肿瘤,其发病率在全球范围内逐年上升。2014年美国胰腺癌新发病例数46420例,死亡病例数39590例,在恶性肿瘤病死率中居第4位,5年生存率不足6%[1]。近年来,胰腺癌治疗理念已由“Surgery First”向“多学科综合诊治团队(multi -disciplinary team, MDT)”模式转变,在肿瘤可切除评估、新辅助治疗、联合血管切除等方面出现了新进展,本文结合最新的美国国立综合癌症网络(NCCN)指南,就胰腺癌外科治疗的热点问题加以讨论,以体现学科的进步,利于国内外学术交流。
出处 《临床肝胆病杂志》 CAS 2015年第5期654-656,共3页 Journal of Clinical Hepatology
关键词 胰腺肿瘤 美国 指南 pancreatic neoplasms United States guidelines
  • 相关文献

参考文献14

  • 1SIEGEL R, MAJ, ZOU Z, et al. Cancer statistics, 2014[J]. CA CancerJ Clin, 2014, 64( 1): 9 -29.
  • 2MEHTA VK, FISHER G, FORDJA, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas[J].J Gastrointest Surg, 2001,5(1): 27 -35.
  • 3CALLERY MP, CHANG KJ, FISHMAN EK, et al. Pretreatment assessment of resectable and. borderline resectable pancreatic cancer: expert consensus statement[J]. Ann Surg Oncol, 2009, 16 (7) : 1727 -1733.
  • 4KATZ MH, MARSH R, HERMANJM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design[J]. Ann Surg Oncol, 2013,20(8): 2787 -2795.
  • 5von HOFF DO, ERVIN T, ARENA FP, et al. Increased survival in pancreatic cancer with nab - paclitaxel plus gemcitabine[J]. N EnglJ Med, 2013, 369(18): 1691 -1703.
  • 6CONROY T, DESSEIGNE F, YCHOU M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N EnglJ Med, 2011,364(19): 1817 -1825.
  • 7BLAZER M, WU C, GOLDBERG RM, et al. Neoadjuvant modified ( m) FOLFIRINOX for locally advanced unresectable (LAPC) and Borderline Resectable (BRPC) adenocarcinoma of the pancreas[J]. Ann Surg Oncol, 2015, 22 (4) : 1153 -1159.
  • 8ZHOU Y, ZHANG Z, LlU Y, et al. Pancreatectomy combined with superior mesenteric vein - portal vein resection for pancreatic cancer: a meta - analysis[J]. WorldJ Surg, 2012, 36(4): 884 -891.
  • 9RAMACCIATO G, MERCANTINI P, PETRUCCIANI N, et al. Does portal - superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma?[J]. Ann Surg Oncol, 2009,16(4): 817 -825.
  • 10KELLY KJ, WINSLOW E, KOOBY 0, et al. Vein involvement during pancreatlcoduodenectornv, is there a need for redefinition of "borderline resectable disease"?[J].J Gastrointest Surg, 2013,17(7): 1209 -1217.

同被引文献107

引证文献14

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部